Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma

NCT ID: NCT00107159

Last Updated: 2013-11-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 37 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-01-31
• Study Completion Date: 2010-09-30

Brief Summary

RATIONALE: Vaccines made from a person's white blood cells and a donor's tumor cells may help the body build an effective immune response to kill tumor cells.

PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with unresected stage III or stage IV melanoma.

Detailed Description

OBJECTIVES:

Primary

• Determine the clinical activity of vaccine therapy comprising autologous dendritic cells pulsed with allogeneic melanoma tumor cell lysates (IDD-3), as measured by tumor control, in patients with unresected stage IIIB or IIIC or stage IV melanoma.

Secondary

• Determine the immunologic activity of this vaccine, as measured by T-cell and antibody responses to lysate or to melanoma antigens or peptides, in these patients.
• Determine the safety of this vaccine, as measured by the incidence and severity of adverse events, in these patients.

OUTLINE: This is an open-label, multicenter study.

Patients undergo apheresis to collect peripheral blood mononuclear cells (PBMCs). The PBMCs are cultured with sargramostim (GM-CSF) and interleukin-13 for the production of dendritic cells. The dendritic cells are then pulsed with lysates from 3 allogeneic melanoma tumor cell lines (IDD-3) to produce the vaccine.

Patients receive vaccine therapy comprising IDD-3 administered as 1 subcutaneous and 5 intradermal injections at each of the 2 uninvolved lymph node-bearing regions once in weeks 0, 2, 4, 6, 8, 10, 16, and 22 in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed at 2, 10, 18, and 26 weeks.

PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 4-12 months.

Conditions

Melanoma (Skin)

Keywords

recurrent melanoma; stage III melanoma; stage IV melanoma

Study Design

• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed primary cutaneous or unknown primary melanoma, including 1 of the following stages:

• Stage IIIB or IIIC disease

• Unresected, in-transit lymph node metastases (N2c or N3)
• Stage IV disease

• Distant skin, subcutaneous, lymph node, or pulmonary metastases (M1a or M1b)

• No cerebral, bone, or other visceral metastases
• At least 1 measurable or evaluable lesion

• Small-volume multiple cutaneous deposits allowed
• Progressive disease, as defined by 1 of the following criteria:

• At least 20% increase in size in ≥ 1 measurable or evaluable lesion
• Appearance of ≥ 1 new lesion since or during last treatment (if applicable) AND within the past 3 months

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• ECOG 0-1

Life expectancy

• At least 6 months

Hematopoietic

• WBC ≥ 3,000/mm^3
• Platelet count ≥ 100,000/mm^3
• Hemoglobin ≥ 10.0 g/dL (transfusion allowed)

Hepatic

• SGOT and SGPT ≤ 2.5 times upper limit of normal (ULN)
• Lactic dehydrogenase normal
• No active hepatitis B or C infection

Renal

• Creatinine ≤ 1.5 times ULN

Immunologic

• No history of autoimmune disease

• Vitiligo allowed
• No history of immunodeficiency syndrome
• No active bacterial, viral, or fungal infection within the past 72 hours
• HIV-1 or -2 negative
• Human T-cell lymphotrophic virus-I or -II negative

Other

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
• No contraindication to apheresis
• No other significant medical or surgical condition that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy

• No prior vaccine therapy with ≥ 1 melanoma antigen or peptide
• More than 4 weeks since prior biologic therapy

Chemotherapy

• More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)

Endocrine therapy

• No concurrent chronic systemic corticosteroids

Radiotherapy

• More than 4 weeks since prior radiotherapy

Surgery

• Not specified

Other

• More than 4 weeks since prior investigational products
• More than 4 weeks since prior chronic systemic immunosuppressive treatment
• No concurrent medication or treatment regimen that would prelude study participation
• No other concurrent anticancer treatment
• No other concurrent immunosuppressive treatment

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

Jonsson Comprehensive Cancer Center

OTHER

Sponsor Role: lead

Principal Investigators

Antoni Ribas, MD

Role: STUDY_CHAIR

Jonsson Comprehensive Cancer Center

Locations

Jonsson Comprehensive Cancer Center at UCLA

Los Angeles, California, United States

Countries

United States

References

Ribas A, Camacho LH, Lee SM, Hersh EM, Brown CK, Richards JM, Rodriguez MJ, Prieto VG, Glaspy JA, Oseguera DK, Hernandez J, Villanueva A, Chmielowski B, Mitsky P, Bercovici N, Wasserman E, Landais D, Ross MI. Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. J Transl Med. 2010 Sep 27;8:89. doi: 10.1186/1479-5876-8-89.

Reference Type: RESULT

PMID: 20875102 (View on PubMed)

Other Identifiers

UCLA-0408080-01

Identifier Type: -

Identifier Source: secondary_id

IDM-DC-MEL-202

Identifier Type: -

Identifier Source: secondary_id

CDR0000422429

Identifier Type: -

Identifier Source: org_study_id